Abstract: A computer-implemented method for synchronizing wireless testing devices includes (a) in a first protocol analyzer located in a first RF-isolated test chamber, capturing first network packets transmitted to or from a wireless device-under-test (DUT) to generate first test data, (b) in a second protocol analyzer located in a second RF-isolated test chamber, capturing second network packets transmitted to or from the wireless DUT to generate second test data, (c) synchronizing internal clocks of the first and second protocol analyzers such that the first and second protocol analyzers capture the first and second network packets with respect to a synchronized internal clock time, and (d) merging the first and second test data using the synchronized internal clock time.

Abstract: A computer-implemented method for synchronizing wireless testing devices includes (a) in a first protocol analyzer located in a first RF-isolated test chamber, capturing first network packets transmitted to or from a wireless device-under-test (DUT) to generate first test data, (b) in a second protocol analyzer located in a second RF-isolated test chamber, capturing second network packets transmitted to or from the wireless DUT to generate second test data, (c) synchronizing internal clocks of the first and second protocol analyzers such that the first and second protocol analyzers capture the first and second network packets with respect to a synchronized internal clock time, and (d) merging the first and second test data using the synchronized internal clock time.

Abstract: Embodiments of this invention are directed to a laser system configured to deliver a pulsed laser beam to a patient's eye. The system includes a laser engine comprising an optically-pumped laser oscillator configured with an extracavity waveplate, and an optional intracavity waveplate, that can be tilted and rotated to provide a limited range of wavelengths for laser mode excitation and to maintain stable mode-locked laser operation. In an embodiment, the present design includes an oscillator and a photosensor, such as a fast photodetector or an autocorrelator, positioned to receive a beam of laser light associated with the oscillator or laser engine, and a controller configured to receive readings from the photosensor and alter the laser gain provided within the oscillator to a level outside the bistable performance zone avoiding mode and gain competitions.

Abstract: A heavy duty, leveraged spare tire carrier utilizes a cross or T-shaped frame configured so a spare tire for an recreational vehicle can be bolted thereto and mounted on a receiver-type hitch common in the RV industry with a secondary receiver hitch mounted thereon. The carrier has an integral lever-actuated lifting and lowering apparatus to allow a single person the ability to remove and replace a spare tire on the carrier and/or to swing the carrier and spare tire out of the way so an engine or other compartment in the rear of an RV can still be accessed.

Abstract: A heavy duty, leveraged spare tire carrier utilizes a cross or T-shaped frame configured so a spare tire for an recreational vehicle can be bolted thereto and mounted on a receiver-type hitch common in the RV industry with a secondary receiver hitch mounted thereon. The carrier has an integral lever-actuated lifting and lowering apparatus to allow a single person the ability to remove and replace a spare tire on the carrier and/or to swing the carrier and spare tire out of the way so an engine or other compartment in the rear of an RV can still be accessed.

Abstract: The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and neurological disorders.

Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of: forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polyester production facility to thereby produce the polyester; heating at least a portion of the reaction medium via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water; flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and heating one or more process fluid streams of the polyester production facility via indirect heat exchange with at least a portion of the lower-pressure steam, wherein the process fluid streams include any stream that is formed predominately of the reaction medium and/or the at lea

Abstract: Integrated processes for making polyesters are disclosed, that include the steps of: (a) producing an aromatic polycarboxylic acid in a monomer production facility; (b) producing a polyester in a polyester production facility, wherein the producing of the polyester comprises the substeps of: (i) forming a polyester reaction medium comprising at least a portion of the aromatic polycarboxylic acid from the monomer production facility, (ii) subjecting at least a portion of the polyester reaction medium to one or more chemical reactions to thereby produce the polyester, (iii) heating the polyester reaction medium at one or more locations in the polyester production facility via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water, and (iv) flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and (c) using at least a portion of the lower

Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polymer production facility to thereby produce the polyester; and heating the reaction medium at one or more locations in the polyester production facility, wherein at least 50 percent of the total energy input employed for the heating of the reaction medium is provided by indirect heat exchange between the reaction medium and steam.

Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of: forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polyester production facility to thereby produce the polyester; generating high-pressure steam having a pressure of at least 5 megapascals; heating one or more process fluid streams of the polyester production facility by indirect heat exchange with the high-pressure steam, wherein the process fluid streams include any stream that is formed predominately of the reaction medium and/or the at least one monomer; heating a heat transfer medium (HTM) via indirect heat exchange with the high-pressure steam to thereby form heated HTM; and heating at least a portion of the process fluid streams by indirect heat exchange with the heated HTM.

Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polymer production facility to thereby produce the polyester; and heating the reaction medium at one or more locations in the polyester production facility, wherein at least 50 percent of the total energy input employed for the heating of the reaction medium is provided by indirect heat exchange between the reaction medium and steam.

Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of: forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polyester production facility to thereby produce the polyester; generating high-pressure steam having a pressure of at least 5 megapascals; heating one or more process fluid streams of the polyester production facility by indirect heat exchange with the high-pressure steam, wherein the process fluid streams include any stream that is formed predominately of the reaction medium and/or the at least one monomer; heating a heat transfer medium (HTM) via indirect heat exchange with the high-pressure steam to thereby form heated HTM; and heating at least a portion of the process fluid streams by indirect heat exchange with the heated HTM.

Abstract: Integrated processes for making polyesters are disclosed, that include the steps of: (a) producing an aromatic polycarboxylic acid in a monomer production facility; (b) producing a polyester in a polyester production facility, wherein the producing of the polyester comprises the substeps of: (i) forming a polyester reaction medium comprising at least a portion of the aromatic polycarboxylic acid from the monomer production facility, (ii) subjecting at least a portion of the polyester reaction medium to one or more chemical reactions to thereby produce the polyester, (iii) heating the polyester reaction medium at one or more locations in the polyester production facility via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water, and (iv) flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and (c) using at least a portion of the lower

Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of: forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polyester production facility to thereby produce the polyester; heating at least a portion of the reaction medium via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water; flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and heating one or more process fluid streams of the polyester production facility via indirect heat exchange with at least a portion of the lower-pressure steam, wherein the process fluid streams include any stream that is formed predominately of the reaction medium and/or the at lea

Abstract: The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

Abstract: The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and neurological disorders.

Abstract: A system for inexpensively updating manufactured mobile homes with decorative window shadows and skirting. Decorative panels are attached to the home by circular metal snaps. The panels may be of vinyl plastic or other suitable material of sufficient thickness to withstand the weather. A base frame is positioned on the ground. The snaps are attached by nails or screws in a conventional manner to the base frame and the lower periphery of the home. The panels have mating snap receivers at their corners which as snapped in place, side by side, between the base frame and the lower periphery of the home structure, thereby forming a skirt surrounding part or all of the structure. The decorative window shadows are panels sized to fit between the windows. These panels are attached to the exterior wall of the home by metal snaps at their corners like the skirting panels.

Abstract: Disclosed is a process for preparing a macrocyclic compound of the formula (I): which is carried out using an intermediate of the formula (II): wherein W, R1 through R4, D, A and R12 are as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Abstract: The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

Abstract: The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.